Cytomegalovirus in Steroid-Refractory Immune Checkpoint Inhibition-Related Colitis.

[1]  A. Shinagare,et al.  Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor , 2019, Abdominal Radiology.

[2]  Wei-min Li,et al.  Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials , 2018, Journal of Cancer Research and Clinical Oncology.

[3]  M. Respondek,et al.  Identification of clinically relevant cytomegalovirus infections in patients with inflammatory bowel disease , 2018, Modern Pathology.

[4]  D. Schadendorf,et al.  Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis. , 2017, European journal of cancer.

[5]  K. Kerr,et al.  Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  C. Langner,et al.  Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. , 2017, Journal of Crohn's & colitis.

[7]  A. Carneiro,et al.  Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis , 2017, Cancer Immunology, Immunotherapy.

[8]  D. V. van Langenberg,et al.  Toward an Algorithm for the Diagnosis and Management of CMV in Patients with Colitis , 2016, Inflammatory bowel diseases.

[9]  A. Pommer,et al.  Anti-TNF-refractory colitis after checkpoint inhibitor therapy: Possible role of CMV-mediated immunopathogenesis , 2016, Oncoimmunology.

[10]  Siddharth Singh,et al.  Antiviral Therapy in Steroid-refractory Ulcerative Colitis with Cytomegalovirus: Systematic Review and Meta-analysis , 2015, Inflammatory bowel diseases.

[11]  Dirk Schadendorf,et al.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[12]  Antoni Ribas,et al.  Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial , 2014, The Lancet.

[13]  Young Sook Park,et al.  Long-Term Outcomes of Cytomegalovirus Reactivation in Patients with Moderate to Severe Ulcerative Colitis: A Multicenter Study , 2014, Gut and liver.

[14]  Young Sook Park,et al.  The Prevalence and Efficacy of Ganciclovir on Steroid-refractory Ulcerative Colitis With Cytomegalovirus Infection: A Prospective Multicenter Study , 2012, Journal of clinical gastroenterology.

[15]  L. Peyrin-Biroulet,et al.  Cytomegalovirus Load in Inflamed Intestinal Tissue Is Predictive of Resistance to Immunosuppressive Therapy in Ulcerative Colitis , 2011, The American Journal of Gastroenterology.

[16]  H. Tilg,et al.  Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. , 2009, Journal of Crohn's & colitis.

[17]  H. Ogata,et al.  Cytomegalovirus Is Frequently Reactivated and Disappears Without Antiviral Agents in Ulcerative Colitis Patients , 2007, The American Journal of Gastroenterology.

[18]  A. Rizzo,et al.  Severe acute colitis associated with CMV: a prevalence study. , 2004, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.